Get the Stockscreener App
240.34
0.48%
1.15
Pre-market:
239.91
-0.43
-0.18%
Natera Inc stock is traded at $240.34, with a volume of 1.01M.
It is up +0.48% in the last 24 hours and up +5.23% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$239.19
Open:
$240.24
24h Volume:
1.01M
Relative Volume:
0.76
Market Cap:
$33.52B
Revenue:
$2.12B
Net Income/Loss:
$-309.19M
P/E Ratio:
-105.22
EPS:
-2.2841
Net Cash Flow:
$93.57M
1W Performance:
+0.33%
1M Performance:
+5.23%
6M Performance:
+60.39%
1Y Performance:
+41.09%
1-Day Range:
$234.51
$243.03
1-Week Range:
$226.12
$243.47
52-Week Range:
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
240.34 | 33.35B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
624.65 | 233.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
239.89 | 168.08B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
712.12 | 56.73B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.28 | 41.10B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
144.83 | 41.37B | 6.95B | 1.30B | 1.15B | 4.5696 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Is It Too Late To Consider Natera (NTRA) After Its Strong 1-Year Share Price Run? - simplywall.st
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity - TipRanks
Sumitomo Mitsui Trust Group Inc. Sells 88,968 Shares of Natera, Inc. $NTRA - MarketBeat
Assessing Whether Natera (NTRA) Is Overvalued After Strong Longer Term Share Price Gains - Yahoo Finance
Natera unveils AI model to enhance cancer recurrence risk assessment By Investing.com - Investing.com Nigeria
How Investors Are Reacting To Natera (NTRA) NVIDIA-Backed Multimodal AI And Precision Diagnostics Advances - Yahoo Finance
Natera’s SCORE Study Builds Real-World Evidence for Cancer MRD Testing - TipRanks
NTRA & NVDA Partner to Improve AI Models for Precision Medicine - TradingView — Track All Markets
Natera, Inc. Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling - marketscreener.com
Natera unveils AI model to enhance cancer recurrence risk assessment - Investing.com
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling - Yahoo Finance
Natera: Accelerating MRD Momentum, Revenue Outperformance, and Improving Cash Profile Support Buy Rating - TipRanks
(NTRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
JP Morgan lifts Natera, Inc. (NTRA) target on Signatera momentum - MSN
Natera’s updated prenatal test, Fetal Focus, adds Gaucher disease - Gaucher Disease News
Natera (NTRA) Joins Forces with NVIDIA to Boost AI in Precision Medicine - GuruFocus
Nvidia enters collaboration with Natera - TipRanks
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA - marketscreener.com
Natera stock rises as Canaccord maintains Buy rating on strong preliminary results - Investing.com Nigeria
Natera stock rises as Canaccord maintains Buy rating on strong preliminary results By Investing.com - Investing.com South Africa
Natera (NTRA) Reports Robust Q4 and FY 2025 Revenue Growth - GuruFocus
Natera Q4 Preliminary Revenue Rises; Shares Up Pre-Bell - marketscreener.com
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth - BioSpace
Natera, Inc. (NTRA) Investor Outlook: Unlocking Growth Potential with 34.7% Revenue Surge - DirectorsTalk Interviews
Natera Q4 prelim revenue beats on oncology tests boost - TradingView — Track All Markets
Breakeven On The Horizon For Natera, Inc. (NASDAQ:NTRA) - Yahoo Finance
Natera, Inc.'s (NASDAQ:NTRA) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Natera (NASDAQ:NTRA) Stock Rating Upgraded by Citigroup - MarketBeat
Market Catalysts: Is Natera Inc. stock attractive after correctionWatch List & Consistent Income Trade Ideas - Улправда
Natera (NTRA) announces publication of findings from randomized, phase III CALGB (Alliance)/SWOG 80702 study - MSN
Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD 9.83 Billion by 2031, Globally, at 17.01% CAGR: Verified Market Research® - GlobeNewswire Inc.
Natera, Inc. $NTRA Shares Acquired by SG Americas Securities LLC - MarketBeat
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Yahoo Finance
Will Natera Inc. stock outperform tech sector in 2025Insider Buying & Real-Time Stock Entry Alerts - ulpravda.ru
Can Natera Inc. stock sustain market leadership2025 AllTime Highs & Risk Controlled Stock Pick Alerts - ulpravda.ru
Is Natera Inc. stock attractive for growth ETFs2025 Top Gainers & Free High Accuracy Swing Entry Alerts - ulpravda.ru
NTRANatera Inc Latest Stock News & Market Updates - Stock Titan
Natera (NASDAQ:NTRA) Shares Down 7.6%What's Next? - MarketBeat
Will Natera Inc. stock gain from strong economyQuarterly Portfolio Report & Risk Adjusted Buy/Sell Alerts - Улправда
Can Natera Inc. stock weather global recessionJuly 2025 Momentum & Reliable Entry Point Alerts - ulpravda.ru
Can Natera Inc. stock beat analyst upgradesJuly 2025 Opening Moves & Real-Time Chart Pattern Alerts - ulpravda.ru
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Finviz
Exelixis and Natera to collaborate on MRD-guided cancer trial By Investing.com - Investing.com Nigeria
Citigroup Initiates Buy Rating on Natera (NTRA) with $300 Price Target | NTRA Stock News - GuruFocus
Assessing Natera (NTRA) Valuation After Positive ALTAIR Trial Data And Expanded Fetal Focus Test Launch - simplywall.st
Medical stock hovers near buy point after 46% gain - MSN
Why Natera’s Stock Is Sliding Despite Bullish Outlook - TipRanks
Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera - CNBC
Exelixis and Natera stocks rise on colorectal cancer trial collaboration By Investing.com - Investing.com Australia
Exelixis and Natera stocks rise on colorectal cancer trial collaboration - Investing.com
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial - marketscreener.com
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):